AlphAIalphai — Financial news for AI agents
insidermonkey.comSEP 82 min read$CCSI

Consensus Cloud’s (CCSI) Buyback Doubles, But Growth Has A Catch

Consensus Cloud Solutions (CCSI) reported Q2 revenue of $91.4M, up 4.1%, and net income of $27.4M, up 31.7%. The board doubled its buyback authorization to $200M. Corporate segment revenue rose 9.3%, while the SoHo business declined 4.7%. Adjusted EBITDA was flat at $48.3M. The company reaffirmed its 2026 guidance and issued steady Q3 guidance.

Original reporting
insidermonkey.com
Published Sep 8, 2026, 4:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 8, 2026, 4:12 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Consensus Cloud’s (CCSI) Buyback Doubles, But Growth Has A Catch — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$CCSINeutralMed
01

Why it matters

The earnings release provides fresh data on revenue growth, cash flow, and buyback policy, informing short‑term trading decisions.

02

Market read

New earnings and buyback information could move the stock in the near term.

03

What to watch

High debt level and rising G&A costs may limit future cash returns.

Relevance 7/10Novelty 8/10Timing: post‑earnings release

Background

Consensus Cloud Solutions (CCSI) is a micro‑cap provider of fax and cloud document exchange services.

Company-level read

Ticker impact

$CCSINeutralMedium confidence
Context

Consensus Cloud reported Q2 results with revenue up 4.1% and raised its buyback authorization to $200 million, providing fresh earnings and guidance data.

Expected impact

Potential modest upside if investors value the larger buyback and guidance.

Evidence & confidence

Guidance remains steady and cash generation is strong, but adjusted margins compressed.

Market effects

Sector

Corporate cloud‑document segment shows growth, may benefit peers in enterprise software.

Regional

U.S. small‑cap tech sector could see modest re‑rating.

Global

Limited to niche cloud‑document market.

Counterpoint

What could challenge this read

Margin compression and SoHo decline could outweigh buyback benefits, leading to price pressure.

Key entities

  • Company
    Consensus Cloud Solutions

    Subject of the earnings report.

Read at source← All news

Related articles

AUG 14
$CCSIMedAI 8/10

Consensus Cloud Solutions (CCSI) Q2 2026 Earnings Call Transcript

Consensus Cloud Solutions (CCSI) reported Q2 2026 revenue of $91.4M (+4.1% YoY). Corporate revenue rose to $60.5M (+9.3%) and SoHo revenue fell to $30.9M (-4.7%). Adjusted EBITDA was $48.3M (52.9% margin) and adjusted EPS was $1.49. Full-year 2026 guidance: $350M-$364M revenue and $182M-$193M adjusted EBITDA.

fool.com6 min
AUG 6
$CCSIHigh

Consensus Cloud Solutions, Inc. (CCSI): Results of Operations and Financial Condition

Consensus Cloud Solutions, Inc. (CCSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Consensus Cloud Solutions, Inc. Reports Second Quarter 2026 Results Reaffirms Full Year 2026 and Releases Q3 2026 Guidance Increases Stock Buyback Program to $200 Million LOS ANGELES -- Consensus Cloud Solutions, Inc. (NASDAQ: CCSI) today reported financial results for the second

SEC EDGAR 8-K5 min
SEP 8
$MNDYHighAI 8/10

Why Monday.com Stock Popped in August

Monday.com (MNDY) stock rose 16% in August, despite initial investor concerns over its Q2 results. Revenue grew 22% YoY to $365M, and adjusted net income increased 13% to $65.6M. The company provided optimistic guidance for Q3 and 2026. A strong earnings report from Salesforce later in the month boosted investor sentiment in the CRM sector, benefiting Monday.com.

yahoo.com2 min
SEP 8
$AQSTMed

Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.

insidermonkey.com3 min
SEP 8
$CRMDMedAI 8/10

CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged

CorMedix (CRMD) reported Q2 revenue of $101.9M, up from $39.7M a year ago, with net income of $26M. Management raised adjusted EBITDA guidance but kept full-year revenue guidance unchanged. DefenCath and the Melinta portfolio drove growth, with new supply agreements signed. The company expects to submit an sNDA for REZZAYO in Q3. Operating expenses increased due to Melinta's costs and R&D spending. Hedge fund ownership rose, while short interest remained high at 22.30%.

insidermonkey.com3 min